A clinical trial led simply by Dana-Farber Cancers Institute investigators shows.

Today by JAMA Oncology In a report published online, the researchers statement that men who had been taking statins since the start of androgen deprivation therapy proceeded to go a median of 27.5 months before their disease started to worsen, in comparison to 17.4 months for men who didn't take statins. The trial included 926 individuals, 70 % of whom had their disease improvement during a six-yr period. This median 10-month advantage in delaying disease progression suggests that statins could be a valuable addition to our current therapies for prostate cancer, says the scholarly research;s first author, Lauren Harshman, MD, medical oncologist at the Lank Middle for Genitourinary Oncology at Dana-Farber.Instead of weakening blood vessels so they don’t feed malignant tumors, these cancer treatments, known as anti-angiogenesis drugs, in fact normalize and strengthen arteries – – and which means they are able to spur tumors to grow larger. For his or her study, experts at the Moores Cancers Middle at the University of California, NORTH PARK in La Jolla, replicated the actions of anti-angiogenesis medications by genetically reducing VEGF levels in mouse tumors and inflammatory cells in several types of cancers, including pancreatic malignancy.